ProMIS Neurosciences (PMN) Issues Letter to Shareholders

Go back to ProMIS Neurosciences (PMN) Issues Letter to Shareholders

ProMIS Neurosciences Issues Letter to Shareholders

January 13, 2025 10:30 AM UTC

CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that its Chief Executive Officer, Neil Warma, issued the following letter to the Companys shareholders.

Dear ProMIS Shareholders,

... More